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Abstract
Introduction: Lupus anticoagulant (LAC) testing is challenging. Most data are derived from a well-controlled study environment with potential 
alterations to daily routines. The aim of this retrospective cohort study was to assess the capacity of various LAC screening tests and derived mixing 
tests to predict a positive result in subsequent confirmation tests in a large cohort of patients. 
Materials and methods: In 5832 individuals, we retrospectively evaluated the accuracy of the aPTT-A, aPTT-LAscreen, aPTT-FS and dRVVTscreen 
and of their derived mixing tests in detecting a positive confirmation test result within the same blood specimen. The group differences, degree of 
correlation and the predictive accuracy of LAC coagulation tests were analysed using the Mann-Whitney U test, the Spearman-rank-correlation and 
by area under the receiver operating characteristic curve (ROC-AUC) analysis. ROC-AUCs were compared with the Venkatramań s permutation test. 
Results: The pre-test probability of patients with clinically suspected LAC was 36% in patients without factor deficiency or anticoagulation the-
rapy. The aPTT-LAscreen showed the best diagnostic accuracy with a ROC-AUC of 0.84 (95% CI: 0.82 – 0.86). No clear advantage of the dRVVT-derived 
mixing test was detectable when compared to the dRVVTscreen (P = 0.829). Usage of the index of circulating anticoagulant (ICA) did not improve the 
diagnostic power of respective mixing tests. 
Conclusions: Among the parameters evaluated, aPTT-LAscreen and derived mixing test parameters were the most accurate tests. In our study co-
hort, neither other mixing test nor the ICA presented any further advantage in LAC diagnostics. 
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Introduction
The detection of lupus anticoagulants (LAC) is 
based on interference testing of the coagulation 
cascade and therefore testing it proves challeng-
ing (1). Several guidelines and expert recommen-
dations exist proposing LAC testing in a stepwise 
procedure including screening, mixing and con-
firmatory tests (2–4). Since no individual screening 
test presents with a high diagnostic accuracy, 
most guidelines recommend the performance of 
two tests for the initial screening, including a test 
based on the diluted Russell Viper venom time 
(dRVVT) and a LAC-sensitive activated partial 
thromboplastin time (aPTT-LAscreen) containing 
low amounts of phospholipids. The aPTT-LAscreen 
appears to display higher sensitivity and the dRV-
VT, described as being the most robust assay for 
LAC testing, might possess a higher specificity for 
detecting LAC (4,5). As an in-house procedure, the 
performance of a mixing test is advocated with a 
1:1 ratio between patient plasma (PP) and pooled 
normal plasma (PNP). With regard to the mixing 
test, there are some differences in the actual 
guidelines. While the International Society on Hae-
mostasis and Thrombosis (ISTH) and the British 
Committee for Standards in Haematology (BCSH) 
recommend a screening-mixing-confirmation test 
Electronic supplementary material available online for this article.
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order, the Clinical and Laboratory Standards Insti-
tute (CLSI) suggests the screening, confirmation 
and mixing test order (2,4,6). According to the lat-
ter guideline, the mixing test should be omitted in 
samples without evidence of other causes of ele-
vated clotting times (CT). Generally, mixing tests 
are used to differentiate between coagulation fac-
tor deficiencies and coagulation inhibitors or treat-
ment with heparin as the cause of a prolonged CT. 
However, due to dilution effects, a negative mix-
ing test result does not rule out the presence of a 
“weak” LAC (6). Likewise, false-positive mixing 
tests can result from interference by therapeutic 
anticoagulants (7). Confirmation testing should be 
conducted with an increased concentration of 
phospholipids compared to screening tests, and a 
ratio between the CT with low and high concen-
trations of phospholipids should be calculated. 
There is no agreement between the guidelines re-
garding LAC testing for patients taking vitamin K 
antagonists (VKA) or heparin. Generally, factor de-
ficiency in patients on VKA with an international 
normalized ratio (INR) above 1.5 can affect LAC 
testing and the results have to be taken with cau-
tion. While CLSI and ISTH suggest caution with re-
spect to the results of LAC testing of patients un-
der heparin therapy, the BCSH recommends no 
LAC testing of such samples at all. 
Due to high demands on laboratory facilities, the 
incurred costs and the wide availability of integrat-
ed confirmation testing, the need for mixing tests 
has to be carefully evaluated. However, there is 
hardly any data for a suspected LAC patient cohort 
with representative pre-test probability of having 
LAC. Hence we conducted a retrospective cohort 
study to evaluate the predictive capacity of vari-
ous LAC screening tests and derived mixing tests 
in detecting a positive confirmation test result 
within the same blood sample in 5832 patients 
without any factor deficiency or anticoagulation 
therapy (dataset A), in patients with heparin thera-
py (dataset B) and in patients on VKA therapy 
(dataset C). Whether or not positive results of con-
firmation testing could be confirmed at a later 
time point (as a criterion for diagnosing antiphos-




This retrospective cohort study was performed 
between 2010 and 2014 at the Vienna General 
Hospital, Medical University of Vienna, Austria, a 
tertiary teaching hospital with 2145 beds. The 
study was approved by the local ethics committee 
(EC-Number: 1197/2013) and was conducted in ac-
cordance with the ethical principles of the Decla-
ration of Helsinki.
Subjects
Due to the retrospective design of the study, in-
formed consent was not obtained from study par-
ticipants. All consecutive patients older than 18 
years of age with clinical suspicion of having LAC 
from whom the treating physician requested LAC 
testing were included. Before requesting coagula-
tion testing, clinicians were obligated to docu-
ment any anticoagulant therapy. Based on this in-
formation, INR measurements (for patients on 
VKA) or anti-Xa-measurements (for patients on 
heparin therapy) were performed. Patients with-
out a complete LAC testing panel, patients with 
known coagulation interfering antibodies other 
than LAC or known haemophilia A, B or contact 
factor deficiency, patients under direct oral antico-
agulants or heparin therapy with anti-Xa activities 
above 1 IU/mL were excluded. A complete LAC 
panel included the following assessment: pro-
thrombin time (PT) according to Owren and Quick, 
thrombin clotting time (TCT), fibrinogen, LAC 
screening tests including aPTT-A (using STA–PTTA 
reagent), aPTT-FS (using Actin FS reagent), aPTT-
LAscreen or dRVVTscreen, and one derived mixing 
test as well as the aPTT-LA- and dRVVT- confirma-
tion tests (see Supplementary figure 1). No pa-
tients were included more than once, as only the 
first LAC request for a patient was included during 
the study period. 
To increase the within-group homogeneity and to 
address the discrepancy between available litera-
ture and recommendations with the clinical daily 
practice, three datasets (Figure 1) were established 
including patients without factor deficiency and 
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without evidence of anticoagulation therapy 
(dataset A), patients with anti-Xa assessment for 
heparin therapy monitoring (dataset B) and pa-
tients with INR assessment for the monitoring of 
VKA therapy (dataset C).
Between January 2010 and December 2014, LAC 
testing was conducted in 9328 patients. In 597 pa-
tients, no full LAC testing panel was available. In 
further 178 patients, the anti-Xa activity for moni-
toring heparin therapy was above 1 IU/mL (Figure 
1). For dataset A, patients with abnormal PT or ex-
trinsic factor deficiencies (N = 3962), intrinsic factor 
deficiencies (N = 1933), abnormal TCT (N = 203), 
abnormal D-dimer concentrations (N = 122), fibrin-
ogen deficiency (N = 18) and patients with Danap-
aroid therapy (heparinoid, inhibiting activated fac-
tor X, N = 3) were excluded. Among the patients of 
dataset A (N = 2312, female-to-male ratio: 52% to 
48%), 35.8% presented with post-test evidence of 
LAC (N = 828, Table 1, dataset A). Among the total 
study population, LAC testing and anti-Xa activi-
ties for monitoring heparin therapy were evaluat-
ed in 1390 patients (dataset B, female-to-male ra-
tio: 53% to 47%). Further 2130 patients on VKA 
therapy were included (dataset C). In dataset C, 
LAC positivity rate was 13% and the female-to-
male ratio was 49% to 51%. We pre-defined INR 
values as sub-therapeutic (INR = 1.31 - 1.99; N = 
536), therapeutic (INR = 2.00 - 3.50; N = 1324) and 
supra-therapeutic (INR > 3.51; N = 270). The com-
Figure 1. Study recruitment process. VKA - vitamin K antagonist. PT - prothrombin time. TCT - thrombin clotting time.
Potential study
participants: 9328
1390 patients with anti-
Xa levels for heparin
monitoring (dataset B)
2130 patients with INR
assessment for VKA
monitoring (dataset C)
2312 patients without factor deciency
and without anticoagulation therapy
 (dataset A)
Exclusion – missing data: 597
Exclusion – abnormal TCT: 203
Exclusion – abnormal D-dimer concentrations: 122
Exclusion – brinogen deciency: 18
Exclusion – anti-Xa > 0.09 IU/mL: 178
Exclusion – therapy with Danaparoid: 3
Exclusion – intrinsic factor deciencies: 1933
Exclusion – abnormal PT of factor deciencies
of the extrinsic/common pathway: 3962
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Parameter LAC negativeN = 1484
LAC positive









PT Owren (%) 103.0 (91.0 – 117.2) 106.5 (95.0 – 123.0) < 0.001 0.56 (0.53 – 0.58)
PT Quick (%) 91.0 (85.0 – 98.0) 92.0 (85.0 – 99.0) 0.363 0.51 (0.49 – 0.54)
TCT (s) 13.7 (13.1 – 14.5) 13.7 (13.0 – 14.4) 0.053 0.48 (0.45 – 0.50)
aPTT-A (s) 43.5 (41.0 – 46.2) 48.8 (44.4 – 56.5) < 0.001 0.76 (0.74 – 0.78)
aPTT-LA (s) 49.9 (45.8 – 54.4) 61.2 (54.8 – 72.3) < 0.001 0.84 (0.82 – 0.86)
aPTT-FS (s) 39.6 (36.7 – 41.9) 37.0 (34.2 – 40.3) < 0.001 0.65 (0.62 – 0.67)
dRVVT (s) 45.8 (41.3 – 50.6) 56.9 (50.3 – 65.8) < 0.001 0.81 (0.79 – 0.83)
Fibrinogen (g/L) 3.77 (3.08 – 4.61) 4.27 (3.47 – 5.50) < 0.001 0.62 (0.59 – 0.64)
FVIII (%) 137 (102 – 190) 174 (132 – 234) < 0.001 0.65 (0.63 – 0.67)
FIX (%) 109 (91 – 129) 123 (102 – 147) < 0.001 0.61 (0.59 – 0.64)
FXI (%) 93 (80 – 107) 98 (84 – 115) < 0.001 0.57 (0.54 – 0.59)
FXII (%) 92 (77 – 113) 96 (80 – 119) 0.003 0.54 (0.51 – 0.56)




N = 512 N = 110
aPTT-A (s) 45.0 (43.4 – 47.6) 50.8 (47.0 – 57.4) < 0.001 0.78 (0.73 – 0.83)
∆Mix–PNP (s) 4.3 (2.6 – 6.2) 8.2 (5.5 – 11.1) < 0.001 0.79 (0.75 – 0.84)





N = 375 N = 476
APTT-LAscreen (s) 56.4 (53.4 – 60.3) 67.5 (59.3 – 81.0) < 0.001 0.80 (0.77 – 0.83)
∆Mix–PNP(s) 6.7 (4.7 – 9.6) 15.8 (10.3 – 25.3) < 0.001 0.84 (0.82 – 0.87)





N = 118 N = 230
dRVVTscreen (s) 58.7 (56.2 – 62.0) 66.8 (60.3 – 76.6) < 0.001 0.77 (0.72 – 0.82)
∆Mix–Norm (s) 5.0 (2.9 – 7.0) 9.1 (5.8 – 15.8) < 0.001 0.77 (0.71 – 0.82)





N = 479 N = 12
aPTT-FS (s) 42.0 (40.5 – 43.8) 44.5 (42.7 – 47.4) 0.002 0.77 (0.65 – 0.88)
∆Mix–Norm (s) 1.5 (0.4 – 2.7) 1.8 (0.9 – 4.3) 0.162 0.62 (0.46 – 0.80)
ICA (%) 3.5 (1.0 – 6.3) 4.3 (2.0 – 8.7) 0.223 0.60 (0.44 – 0.77)
Data are derived from patients without factor deficiency or anticoagulant therapy. P < 0.05 considered statistically significant 
(after application of the Bonferroni-Holm correction). *Comparison between patients with and without lupus anticoagulants 
(LAC), using Mann–Whitney U test. ROC - area under the receiver operating characteristics curve, presented with 95% confidence 
intervals (CI). PT Owren - prothrombin time according to Owren. PT Quick - prothrombin time according to Quick. TCT - thrombin 
clotting time. aPTT-A - activated partial thromboplastin time determined using STA–PTTA reagent (Roche Diagnostics). aPTT-FS - 
activated partial thromboplastin time determined using Actin FS (Siemens Healthcare GmbH). aPTT-LA - LAC-sensitive activated 
partial thromboplastin time. dRVVT - diluted Russell Viper venom time. PNP - pooled normal plasma. ICA - index of circulating 
anticoagulant. †aPTT-FS is not recommended for LAC-testing.
Table 1. Coagulation parameters assessed in dataset A
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parison of the dRVVT was not performed, since 
the dRVVT was routinely not assessed in patients 
with (acquired) FX deficiency.
Methods
Blood samples were collected in siliconized tubes 
(Vacuette®, Greiner Bio-One, Kremsmünster, Aus-
tria) with 0.023 M pre-filled sodium citrate (final 
concentration). In accordance to the H-60-A CLSI 
guideline, all samples were first centrifuged at 
2500xg for 15 minutes at 15 °C (Mikro 220 R, Bartelt 
GmbH, Graz, Austria), transferred to a secondary 
polypropylene tube (5 mL, 75 x 13mm PP, Sarstedt 
AG & Co, Nümbrecht, Germany) and again centri-
fuged under the same conditions to obtain plate-
let-poor plasma (platelet counts: < 10 x109/L). Ex-
cept LAC confirmatory testing, all coagulation 
analyses were conducted by using freshly drawn 
samples within 4 hours after blood taking. Thawed 
plasma specimens, stored below - 70°C upon anal-
ysis, were used for LAC confirmatory testing. Rea-
gents, analysers and established reference ranges 
are summarized in Supplementary table 1 and 
quality control materials as well as their coefficient 
of variation are presented in Supplementary table 
2. All test procedures were conducted according 
to the manufacturer ś recommendations. Using a 
coagulometric method, PT Owren (Normotest, 
Technoclone GmbH, Vienna, Austria), PT Quick 
(Thromborel S, Siemens Healthcare GmbH, Erlan-
gen, Germany), TCT (STA-Thrombin, Roche Diag-
nostics, Rotkreuz, Switzerland), fibrinogen (STA–
liquid Fib, Roche Diagnostics), activated partial 
thromboplastin time (aPTT-A, STA–PTTA, Roche 
Diagnostics), aPTT-LAscreen (PTT LA, Roche Diag-
nostics), factor sensitive activated partial thrombo-
plastin time (aPTT-FS, ACTIN FS, Siemens Health-
care GmbH, Erlangen, Germany), dRVVT (DRVV 
SCREEN 2 reagent, Life Diagnostics, West Chester, 
USA) and dRVVT confirmation test (dRVVTconfirm, 
DRVV CONFIRM reagent, Life Diagnostics, West 
Chester, USA) were assessed on the STA-R Evolu-
tion (Diagnostica Stago S.A.S, Asnières sur Seine, 
France). The aPTT-LA confirmation test (LAconfirm, 
Staclot LA, Roche Diagnostics) was applied on the 
MC10 PLUS (ABW Medizin und Technik GmbH, 
Lemgo, Germany).
On the Sysmex CA-7000 (Siemens Healthcare 
GmbH, Erlangen, Germany) analyser, the coagula-
tion factors VIII (FVIII), IX (FIX), XI (FXI) and XII (FXII) 
were determined by one-stage coagulometric 
methods in a multidilution procedure using Actin 
FS reagent (Siemens Healthcare GmbH, Erlangen, 
Germany) and appropriate factor deficient plasmas 
(for FVIII and FIX: Technoclone GmbH, and for FXI 
and FXII: Siemens Healthcare GmbH). For the LAC 
screening procedure the aPTT-A, aPTT-FS, aPTT-
LAscreen, and dRVVTscreen were applied. The LAC 
screening parameter with the largest absolute dif-
ference between our established upper cut-off val-
ue and the measured CT was used for the mixing 
test procedure. The results of the mixing tests are 
presented in Table 1, Supplementary table 3 and 
Supplementary table 4 as subgroups of the corre-
sponding total population. In dataset A, the mixing 
test was performed using the aPTT-A in 622 pa-
tients, the aPTT-LA in 851 patients, the aPTT-FS in 
491 patients and the dRVVT in 348 patients (Table 
1). The same approach was used in dataset B (see 
Supplementary table 3) and dataset C (see Supple-
mentary table 4). Due to the low number of LAC-
positives in subgroups of datasets B and C, the ac-
curacy of the aPTT-FS derived mixing test parame-
ters was not assessed. According to the CLSI H60-
AE guideline, normal pool plasma (PNP) prepared 
from plasma samples of 20 apparently healthy vol-
unteers was used for mixing test studies. The mix-
ing test was performed by mixing one part of pa-
tient plasma with one part of PNP using a 1:1 ratio 
on a STA-R Evolution (Diagnostica Stago S.A.S, As-
nières sur Seine, France). The difference between 
PNP and the corresponding 1:1 mixing sample 
(∆Mix–PNP) was computed. Further the index of 
circulating anticoagulant (ICA, Rosner Index) was 




For the LAconfirm (Staclot LA reagent, Roche Diag-
nostics, Rotkreuz, Switzerland) assessment, patient 
plasma is mixed with reagent buffer 1 (tube 1) or 
with reagent buffer 2 (containing phospholipids, 
tube 2) and incubated for 9 minutes at 37 °C. After-
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wards human plasma (reagent 3) was added to 
both tubes, and incubated for one minute and fi-
nally lyophilized PTT-LS reagent (reagent 4) was 
added and incubated for another five minutes. CTs 
were measured after adding CaCl2 (0.025 M, pre-
incubated at 37 °C). The dRVVTconfirm (DRVV Con-
firm reagent, Life Diagnostics, West Chester, USA) 
assessment was again carried out in two separate 
reactions. Patient plasma was mixed either with 
DRVV-Screen reagent or with the DRVV-Confirm 
reagent containing excess phospholipid concen-
tration (all pre-incubated at 37 °C). After adding 
the pre-incubated starting reagent, both CTs were 
measured and the ratio between CTscreen and CT-
confirm was calculated.
Both confirmation tests, which are widely used, 
were applied in all patients. Confirmation testing 
and occurrence of LAC was considered positive 
when either LAconfirm decreased CT (CTtube1 – CT-
tube2) for more than 3 s or the ratio of dRVVTscreen 
to the dRVVTconfirm was above 1.25 within the 
same sample. The LAC confirmatory cut-offs were 
established by in-house evaluations. According to 
our standard operation procedures, the dRV-
VTscreen was not assessed in patients with heredi-
tary or acquired FX deficiency. All analyses were 
performed under standardized conditions at the 
Department of Laboratory Medicine, which main-
tains a certified (according to ISO 9001:2008) and 
accredited (according to ISO 15189:2008) quality 
management system. 
Statistical analysis
Metric data are given as median (interquartile 
range, IQR) and occurrence of normal distribution 
was analysed using the Shapiro-Wilk test. Group-
differences of metric data were compared by apply-
ing Mann-Whitney U tests. The diagnostic perfor-
mance of parameters was analysed using the area 
under the receiver operating characteristics curve 
(ROC-AUC). Since no perfect LAC screening test ex-
ists and the majority of relevant guidelines recom-
mend the utilization of at least two screening tests, 
the correlation between LAC screening parameters 
was assessed by the Spearman correlation coeffi-
cients and graphically presented as a correlogram 
(Corrgram package, see Figure 2). To enable a better 
overview of scatterplots, 1 % outliers were eliminat-
ed according to the Mahalanobis distance criterion 
using the multivariate outlier package. For finding 
an optimal cut-off point of a diagnostic test, the 
Youden Index method was used. 95% confidence 
intervals (CI) of the ROC-AUC and of binary outcome 
measures were computed with 2000 stratified 
bootstrap-replicates (9). Dependent or independ-
ent ROC-AUCs were compared using a distribution-
free permutation test according to Venkatraman, 
implemented in the pROC package. Statistical sig-
nificance was defined as P-values less than 0.05. 
Where appropriate, an error related to multiple test-
ing was corrected using the Bonferroni-Holm meth-
od. All statistical analysis was conducted using R 
(Version 3.2.2, R Foundation for Statistical Comput-
ing, Vienna, Austria). 
Results
LAC testing in patients without factor 
deficiency of anticoagulation therapy
In dataset A, including 2312 patients without co-
agulation factor deficiency and without evidence 
of anticoagulation therapy, the LAC confirmation 
test positivity was 35.8%. The highest ROC-AUCs 
among the screening parameter revealed the 
aPTT-LAscreen with 0.84 (95% CI: 0.82 – 0.86, see Ta-
ble 1, Figure 3), which was significantly better than 
the dRVVTscreen with 0.81 (95% CI: 0.79 – 0.83, P < 
0.001, see Table 2). Among the screening parame-
ters, the aPTT-A and aPTT-LAscreen presented a 
high correlation to each other (ρ = 0.78, P < 0.001; 
Figure 2). 
The mixing test was performed only in the test 
system showing the largest absolute deviance 
from the upper reference range, which are pre-
sented as subgroups in Table 1 and Table 2. Within 
the mixing test, the best ROC-AUC was found in 
the aPTT-LA ∆Mix–PNP with 0.84 (95% CI: 0.82 – 
0.87; Figure 3), which was significantly better than 
the ROC-AUC of the dRVVT ∆Mix–PNP (0.77, 95% CI: 
0.71 – 0.82, P = 0.016). Furthermore, the aPTT-LA 
∆Mix–PNP and aPTT-A ∆Mix–PNP with 0.79 ROC-
AUC (95% CI: 0.75 – 0.84) had significantly better 
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ts aPTT-A ROC-AUC: 0.76 (0.74 – 0.78) P < 0.001 P < 0.001
aPTT-LAscreen P < 0.001 ROC-AUC: 0.84 (0.82 – 0.86) P = 0.037
dRVVTscreen P < 0.001 P = 0.037 ROC-AUC: 0.81 (0.79 – 0.83)





aPTT-A ROC-AUC: 0.78 (0.73 – 0.83) P = 0.816 P = 0.384
∆Mix–PNP(s) P = 0.816 ROC-AUC: 0.79 (0.75 – 0.84) P < 0.001






APTT-LAscreen ROC-AUC: 0.80 (0.77 – 0.83) P = 0.005 P = 0.257
∆Mix–PNP P = 0.005 ROC-AUC: 0.84 (0.82 – 0.87) P < 0.001






dRVVTscreen ROC-AUC: 0.77 (0.72 – 0.82) P = 0.829 P = 0.247
∆Mix–PNP P = 0.829 ROC-AUC: 0.77 (0.71 – 0.82) P < 0.001
ICA P = 0.247 P < 0.001 ROC-AUC: 0.74 (0.69 – 0.80)
ROC-AUC - area under the receiver operating characteristics curve, presented with 95% confidence intervals (CI), of the screening 
test and mixing test parameters (dataset A patients). P-values were calculated using the permutation test according to Venkatraman 
for dependent ROC-AUCs. P < 0.05 was considered statistically significant (after applying the Bonferroni-Holm correction). aPTT-A - 
activated partial thromboplastin time determined using STA–PTTA reagent (Roche Diagnostics). aPTT-LA - LAC-sensitive activated 
partial thromboplastin time. dRVVT - diluted Russell Viper venom time. PNP - pooled normal plasma. ICA - index of circulating 
anticoagulant. aPTT-FS is not displayed since this test in not recommended for LAC testing.
Table 2. Comparison of the predictive accuracy of LAC screening and mixing test derived parameters
diagnostic accuracy than the aPTT-FS ∆Mix–PNP 
(0.62, 95% CI: 0.46 – 0.79, P = 0.002 and P = 0.019, 
respectively), which is not recommended for LAC 
testing. When comparing the LAC screening test 
with the corresponding ∆Mix–PNP mixing test re-
sult, significant improvement was only found for 
the aPTT-LA (P = 0.005, see Table 2), while the 
∆Mix–PNP did not improve diagnostic accuracy in 
the aPTT-A (P = 0.816), and the dRVVTscreen (P = 
0.829). Calculation of ICA significantly decreased 
the performance of the ∆Mix–PNP parameters in 
the aPTT-A, aPTT-LA, and dRVVT (all: P < 0.001). Ta-
ble 3 presents an overview of the diagnostic per-
formance of binarized mixing test results. At an 
optimal cut-off threshold, the aPTT-LA ∆Mix–PNP 
(cut-off: 10.70 s) presented with 73.5% sensitivity 
and 82.4% specificity, while the dRVVT resulted in 
67.8% sensitivity and 76.3% specificity (cut-off: 
6.75 s). A trend analysis of resulting sensitivities 
and specificities over the course of 12 seconds is 
shown in Table 4.
LAC testing in patients with heparin or VKA 
therapy
In 1390 patients of dataset B (LAC positivity rate: 
16.3%), 319 patients presented with heparin thera-
py (up to 1 IU/mL anti-Xa activity). In these pa-
tients, a tendency for lower ROC-AUCs to detect 
LAC was found in all aPTT-A- and aPTT-LA-derived 
parameters (see Supplementary table 3). Due to 
the considerably low sample size of patients with 
heparin therapy, statistical significance was 
achieved in none of the ROC-AUC differences with 
the exception of the aPTT-FS (assessed in all pa-
tients, P = 0.002).
In patients with VKA (dataset C, N = 2130), the LAC 
positivity rate ranged between 11.1% and 16.7% 
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with VKA therapy were statistically compared to 
those patients without evidence of factor deficien-
cy and anticoagulation therapy (dataset A, see Fig-
ure 1 and Table 1). Notably, several aPTT-LA de-
rived parameters showed significantly better re-
sults in patients with VKA therapy than in the con-
trol group (Prange < 0.001 to 0.969). 
Discussion
The majority of data assessing the diagnostic ca-
pacity of LAC testing is derived from a well-con-
trolled study environment, which possesses sever-
al alterations to the daily clinical routine (10). 
Therefore, we have conducted this retrospective 
cohort study, to assess the predictive capacity of 
LAC screening and mixing test parameter for de-
tecting a positive result in confirmation tests with-
in the same blood sample. Reassessment of a posi-
tive confirmation test (as a criterion for diagnosing 
APL-syndrome) was not goal of this study.
In patients without factor deficiency and without 
anticoagulation therapy (dataset A, N = 2312), the 
LAC positivity rate was 36%. Within dataset A pa-
tients, the highest ROC-AUCs for detecting LAC 
were found by using the aPTT-LAscreen and the 
aPTT-LA mixing test derived parameters. The 
aPTT-LA ∆Mix–PNP performed significantly better 
Figure 2. Correlation of LAC parameters. 
Spearman correlation coefficients ρ are presented with their 
corresponding significance levels; for a better overview of the 
scatterplots, 1 % outliers were eliminated according to the Ma-
halanobis distance criterion using the multivariate outlier pack-
age; aPTT-A, aPTT-LA, aPTT-FS and dRVVT are the screening 









ROC-AUC (95% CI) 0.79 (0.75 – 0.84) 0.84 (0.82 – 0.87) 0.77 (0.71 – 0.82) 0.62 (0.45 – 0.79)
Cut-off (s) * 6.35 (4.65 – 7.95) 10.70 (9.65 – 11.85) 6.75 (5.90 – 10.15) 1.75 (0.45 – 6.45)
Sensitivity (%) 70.9 (54.6 – 88.2) 73.5 (67.2 – 78.8) 67.8 (45.2 – 78.7) 66.7 (16.7–100.0)
Specificity (%) 78.4 (57.4 – 90.8) 82.4 (76.5 – 88.0) 76.3 (62.7 – 94.1) 60.4 (24.8 – 99.8)
NPV (%) 92.6 (90.0 – 96.0) 71.0 (67.2 – 74.8) 54.6 (46.3 – 62.4) 98.8 (97.9 – 100.0)
PPV (%) 40.9 (30.7 – 58.0) 84.2 (80.5 – 88.1) 85.0 (79.7 – 94.3) 5.0 (3.0 – 75.0)
ROC-AUC - area under the receiver operating characteristics curve, presented with 95% confidence intervals (95% CI). NPV - 
negative predictive value, PPV - positive predictive value. aPTT-A - activated partial thromboplastin time determined using STA–
PTTA reagent (Roche Diagnostics). aPTT-LA - LAC-sensitive activated partial thromboplastin time. dRVVT - diluted Russell Viper 
venom time. aPTT-FS - activated partial thromboplastin time determined using Actin FS (Siemens Healthcare GmbH). aPTT-A vs. 
aPTT-LA: P = 0.095, aPTT-A vs. aPTT-FS: P = 0.019, aPTT-A vs. dRVVT: P = 0.635, aPTT-LA vs. aPTT-FS: P = 0.002, aPTT-LA vs. dRVVT: 
P = 0.016, aPTT-FS vs. dRVVT: P = 0.052. *Cut-off value assessed via the Youden index method; †aPTT-FS is not recommended for 
LAC-testing.
Table 3. Diagnostic accuracy of the mixing tests (∆Mix–PNP) assessed
(see Supplementary table 3). While the accuracy of 
the aPTT-A mixing test was lower in patients with 
INR > 3.51, this effect was not seen in the aPTT-LA 
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Threshold (s)
Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI)
aPTT-A aPTT-LA
1 98.2 (95.5 – 100.0) 8.4 (6.1 – 10.9) 99.4 (98.5 – 100.0) 5.1 (2.9 – 7.2)
2 94.6 (90.0 – 98.2) 15.6 (12.5 – 18.8) 99.2 (98.3 – 99.8) 10.9 (7.7 – 14.1)
3 94.6 (90.0 – 98.2) 29.3 (25.6 – 33.4) 97.7 (96.2 – 99.0) 16.5 (12.8 – 20.3)
4 89.1 (82.7 – 94.6) 45.3 (41.0 – 49.2) 96.9 (95.2 – 98.3) 21.1 (17.1 – 25.3)
5 80.9 (73.6 – 88.2) 60.4 (56.3 – 64.5) 95.8 (93.9 – 97.5) 27.5 (23.2 – 32.3)
6 70.0 (60.9 – 79.1)* 73.6 (69.5 – 77.3)* 92.7 (90.1 – 95.0) 43.2 (38.7 – 48.3)
7 60.0 (50.9 – 69.1)* 83.6 (80.3 – 86.9)* 88.5 (85.5 – 91.2) 52.3 (47.2 – 57.3)
8 54.6 (45.5 – 63.6) 89.7 (87.1 – 92.4) 84.7 (81.3 – 87.8) 62.4 (57.3 – 67.2)
9 40.0 (30.9 – 49.1) 93.0 (90.8 – 95.1) 79.8 (75.8 – 83.4) 71.7 (66.9 – 76.3)
10 32.7 (23.6 – 41.8) 95.1 (93.2 – 96.9) 76.1 (72.1 – 79.8)* 77.6 (73.3 – 81.6)*
11 26.4 (18.2 – 34.6) 96.1 (94.3 – 97.7) 72.1 (68.1 – 76.1)* 82.7 (78.7 – 86.4)*
12 23.6 (15.5 – 31.8) 97.1 (95.5 – 98.4) 65.8 (61.6 – 70.0) 86.1 (82.7 – 89.3)
dRVVT aPTT-FS†
1 97.8 (95.7 – 99.6) 11.9 (5.9 – 18.6) 66.7 (41.7 – 91.7)* 37.0 (32.4 – 41.1)*
2 95.7 (92.6 – 98.3) 18.6 (11.9 – 25.4) 41.7 (16.7 – 66.7)* 61.2 (56.8 – 65.6)*
3 93.0 (89.6 – 96.1) 25.4 (18.6 – 33.9) 33.3 (8.3 – 58.3) 77.9 (74.1 – 81.4)
4 88.3 (83.9 – 92.2) 34.8 (26.3 – 43.2) 25.0 (0.0 – 50.0) 88.9 (86.0 – 91.7)
5 83.5 (78.7 – 88.3) 49.2 (40.7 – 58.5) 25.0 (0.0 – 50.0) 96.2 (94.6 – 97.7)
6 74.4 (68.7 – 80.0)* 65.3 (56.8 – 73.7)* 25.0 (0.0 – 50.0) 98.3 (97.1 – 99.4)
7 66.5 (60.4 – 72.6)* 74.6 (67.0 – 82.2)* 8.3 (0.0 – 25.0) 99.6 (99.0 – 100.0)
8 56.1 (50.0 – 62.2) 83.1 (76.3 – 89.0) 8.3 (0.0 – 25.0) 99.8 (99.4 – 100.0)
9 50.4 (44.4 – 57.0) 86.4 (80.5 – 92.4) 8.3 (0.0 – 25.0) 100.0 (100.0 – 100.0)
10 44.8 (38.7 – 51.3) 90.7 (85.6 – 95.8) 8.3 (0.0 – 25.0) 100.0 (100.0 – 100.0)
11 37.4 (31.3 – 43.5) 94.1 (89.8 – 98.3) 0.0 (0.0 – 0.0) 100.0 (100.0 – 100.0)
12 94.9 (90.7 – 98.3) 33.5 (27.8 – 39.6) 0.0 (0.0 – 0.0) 100.0 (100.0 – 100.0)
Sensitivity and specificity are presented in % (with corresponding 95% confidence intervals). *The range of the optimal cut-off 
value according to the Youden index method (see Table 3). aPTT-A - activated partial thromboplastin time determined using STA–
PTTA reagent (Roche Diagnostics). aPTT-LA - LAC-sensitive activated partial thromboplastin time. †aPTT-FS is not recommended 
for LAC-testing
Table 4. Trend analysis of the diagnostic sensitivity and specificity of ∆Mix–PNP
than the dRVVT ∆Mix–PNP. Although guidelines 
describe the dRVVT as being more specific for de-
tecting LAC or particularly emphasize its usage, a 
better performance of aPTT-derived testing sys-
tems than dRVVT-based parameters can also be 
found in the literature, with fewer false negative 
and false positive results or more true positive re-
sults (4,6,11,12). However, a considerable variability 
exists between various reagent and analyser com-
binations, limiting the generalizability of study re-
sults (13). In 2010, LAC testing data from four con-
secutive testing surveys, conducted by The North 
American Specialized Coagulation Laboratory As-
sociation (NASCOLA), was published using com-
mercially available lyophilized plasma samples. 
When assessing a low-titre LAC plasma pool, the 
dRVVT screening test resulted in 7.5% false nega-
tive results and the dRVVT mixing test indicated 
9.5% false negatives, while the LAC sensitive aPTT 
screening test presented with 3.0% false-negative 
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results and the aPTT mixing test resulted in 4.7% 
false negatives. Further, when assessing a normal 
plasma pool, the LAC-sensitive aPTT and dRVVT 
resulted in a similar range of false positive results 
(7.4% vs. 7.8%, respectively) (11).
The ROC-AUC of dRVVTscreen was higher than those 
ROC-AUCs of dRVVT-derived mixing parameters. 
This effect was not observed in aPTT-LA derived 
parameters. Although these differences were not 
statistically significant, the use of the dRVVT mix-
ing test should be carefully evaluated. A clear ben-
efit of the dRVVT mixing test was not observed in 
this cohort. This finding adds to the controversial 
discussion regarding the clinical need for the mix-
ing test, especially in the context of integrated test 
systems (14–18). Generally, mixing tests might in-
crease the specificity while potentially decreasing 
the sensitivity by diluting effects of specimens 
with weak antibodies (19,20). However, when mix-
ing tests are omitted, false negative results related 
to a very strong LAC, but false positives especially 
in patients with VKA have also been reported 
(21,22). In this regard, the BCSH guideline consid-
ers specimens without other causes of prolonged 
CT, negative mixing tests but positive screening 
and confirmation tests as LAC positive (6). Further-
more, the lupus cofactor has been described as a 
heterogeneous and imprecisely characterized 
phenomenon, which is detectable when adding 
PNP to the PP (23,24). Therefore, the mixing test 
might have a significant value in some selected 
patients, but implies a low cost-effectiveness in 
widespread use. In this regard, our findings are 
concordant with the recommendations of the CLSI 
guidelines, which advocate the usage of the mix-
ing test only in unclear cases (2). In our opinion, a 
predictive model established with LAC screening 
coagulation tests using linear or non-linear meth-
ods might have a better diagnostic accuracy than 
mixing test studies in a widespread application.
Further, the usefulness of the ICA is controversially 
discussed in literature (25). While the ISTH guide-
line suggests its usage as an alternative approach, 
in our evaluation, no benefit has been found for 
calculating the ICA or the ∆PP–PNP compared to 
∆Mix–PNP. This is in line with several recent studies 
using different patient settings (12,16,26).
Figure 3. Comparison of ROC-AUCs of LAC screening parameters. 
(A) Dependent ROC-AUCs with corresponding 95% confidence intervals (all dataset A patients); aPTT-A: 0.76 (0.74 – 0.78), aPTT-LA 
0.84 (0.82 – 0.86), aPTT-FS: 0.65 (0.62 – 0.67), dRVVT: 0.81 (0.79 – 0.83). 
(B) Independent ROC-AUCs with corresponding 95% confidence intervals (patient subgroups according to the mixing test per-
formed): aPTT-A: 0.79 (0.75 – 0.84), aPTT-LA: 0.84 (0.82 – 0.87), aPTT-FS: 0.62 (0.46 – 0.79), dRVVT: 0.77 (0.71 – 0.82). aPTT-FS is not rec-
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Although usage of the aPTT-FS for the mixing test 
is not recommended in current guidelines, we per-
formed this procedure in 491 patients (including 
12 patients with evidence of LAC, dataset A) whose 
difference to the reference value was the highest 
in the aPTT-FS among the LAC screening parame-
ters. Typically this occurred in patients with factor 
deficiency. These patients were presented in the 
results section, since their deletion would have al-
tered the pre-test probability of a positive confir-
mation test, and since it is important to make clear 
the inappropriateness of such an algorithm. Even 
with an optimal threshold of only 1.75 s, the aPTT-
FS ∆Mix–PNP presented with only 66.7% sensitivi-
ty, which clearly restricts its usefulness for LAC 
testing. To prevent a potential impact of the inap-
propriate aPTT-Actin FS on the overall study re-
sults, the diagnostic accuracy analysis of screening 
tests were split and statistical comparison of aPTT-
Actin FS to LAC-sensitive screening tests was 
avoided.
Interestingly, the FVIII, FIX, FXI, FXII activities and 
fibrinogen concentrations had some predictive ca-
pacity for identifying patients with LAC. For all five 
parameters, patients with LAC had significantly 
higher levels than patients without evidence of 
LAC. This might be based on an acute phase reac-
tion or an inflammatory response reaction, which 
might be accompanied with the expression of LAC 
or be based on an infectious genesis of the expres-
sion of LAC (27). Further, since a relatively large co-
hort was analysed, small differences between the 
LAC positive and LAC negative patients yield into 
statistical significance. Moreover, statistical signifi-
cance does not necessarily imply clinical relevance 
and ROC-AUC analysis results are in our case better 
suited to estimate the effect sizes of LAC testing 
parameters. In patients on heparin (anti-Xa activity 
≤ 1 IU/mL), the diagnostic performance of LAC pa-
rameters was remarkably lower than in those with-
out heparin. However, apart from the aPTT-FS, 
these differences were not statistically significant, 
which might be related to the relatively small sam-
ple size in some subgroups. 
Generally, recent guidelines recommend LAC test-
ing after discontinuation of VKA therapy. However, 
in daily clinical practice LAC testing is also request-
ed in patients under VKA therapy especially as dis-
continuation of the VKA therapy is not always fea-
sible. Therefore, patients with heparin or VKA were 
evaluated separately in our statistical analysis. The 
effect of non-vitamin K antagonist oral anticoagu-
lants (NOACs) was not evaluated, since NOACs 
were hardly used in Austria during the study peri-
od. According to the manufacturer ś instruction 
sheet (StaClot-LA direction for use, Version 4) the 
test is insensitive to heparin up to 1 IU/mL due to a 
heparin inhibitor and no false positive result was 
found in patients under VKA therapy. In the case 
of dRVVT confirmation test, no precise informa-
tion is given in the manufacturer ś instruction 
sheet on testing patients with heparin or with VKA 
(#140 0312A). According to our data, LAC testing in 
patients taking VKA was not statistically impaired 
in comparison to those patients without VKA 
(dataset A). 
The aPTT-LA-derived parameters presented with 
partly better ROC-AUCs in patients with VKA than 
in the control cohort. This finding might indicate 
that the presence of LAC is more easily unmasked 
in patients on VKA than in patients without factor 
deficiency. However, the pre-test probability for 
having LAC or the positivity rate of confirmation 
tests might be altered in these selected patients. 
Further prospective studies are needed to assess 
the possibility to evaluated LAC testing in patients 
with VKA. Alternatively, an additional dilution step 
of patient’s plasma and PNP in patients with VKA 
might be considered. However, our results are 
concordant with the literature, which indicates the 
possibility of LAC testing in patients with VKA (28–
30). Moreover, the usage of proper dRVVT cut-off 
values or a combination of dRVVT and aPTT-based 
results for LAC testing in patients with VKA are 
proposed (30). 
For this retrospective cohort study approach, sev-
eral limitations have to be addressed. Although 
the overall sample size is considerably large, a big-
ger sample size would be needed for some sub-
group analyses. LAC positivity was defined as a 
positive result of the aPTT-LA or/and dRVVT-based 
confirmation test in the same plasma sample, thus 
false positive or false negative confirmation test 
results could not be ruled out. Finally, in our labo-
Biochem Med (Zagreb) 2017;27(3):030705  https://doi.org/10.11613/BM.2017.030705 
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ratory the established reference range of the aPTT-
LAscreen extends up to 49 seconds, which is longer 
than in most other coagulation laboratories. 
Therefore, only patients with a higher probability 
of having LAC were assessed using the aPTT-LA 
mixing test, which might alter the test’s diagnostic 
accuracy. However, the diagnostic accuracy of the 
aPTT-LAscreen was significantly higher when com-
pared to the dRVVTscreen (0.84 vs. 0.81, P = 0.037) 
assessed in all dataset A patients.
In conclusion, the pre-test probability of patients 
with clinically suspected LAC was 36% in patients 
without factor deficiency or anticoagulation thera-
py. The aPTT-LA-derived parameters showed a bet-
ter diagnostic accuracy for identifying LAC than 
dRVVT-derived parameters. Usage of the mixing 
test had no further advantage in the LAC diagnos-
tics and the ICA did not improve the performance 
of the mixing test. According to the results of this 
study, no impairment was found in patients with 
VKA, while patients with heparin presented with 
considerably lower diagnostic accuracy.
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